Post-market surveillance (PMS) is complex and often misunderstood by device manufacturers. Europe's new Medical Devices Regulation (MDR) adds to the complexity of complying with specific PMS and post-market clinical follow-up (PMCF) requirements. Many companies will need to maintain more robust PMS procedures and perform more PMCF studies to meet their Notified Body’s expectations. In this free webinar, we will discuss new European PMS and PMCF requirements.
What will you learn:
ABOUT THE PRESENTER:
Ronald Boumans is a Senior Regulatory Consultant at Emergo's office in The Hague with 30+ years of experience in the medical device industry. Prior to joining Emergo, he served as Inspector of Medical Technology at the Dutch Healthcare Inspectorate (IGZ). Ronald’s expertise includes European medical device legislation, Competent Authority supervision, and CE Marking requirements. He is a member of the EUDAMED Steering Committee and the EUDAMED post-market surveillance, vigilance, and data exchange working groups.
自2018年起,美国食品和药物管理局(U.S. Food and Drug Administration,FDA)开始试行以电子化方式来帮助行业提供完整的510(k)上市前通知。2022年,为推进以电子格式提供510(k)递交文件的过渡,美国FDA正式发布关于使用电子递交模板和资源的最终指导文
阅读更多新欧盟医疗器械法规2017/745(MDR)新增了对公告机构开展临床评估审查的新要求。该审查新要求的提出将对部分在从医疗器械法令MDD到新医疗器械法规MDR过渡中的医疗器械企业带来面临不符合项的风险。 对此,此场研讨会将特此分享在新欧盟医疗器械法规MDR下,医疗器械如何满足临床评
阅读更多